Author:
Fabbrini P.,Finkel K.,Gallieni M.,Capasso G.,Cavo M.,Santoro A.,Pasquali S.
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. Dimopoulos MA, Terpos E, Chanan-Khan A et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976–4984
2. Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG (2012) Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol 5:51–66
3. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA (2012) Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res 18:2145–2163
4. Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, Herrera GA, Lachmann H, Sanders PW, International Kidney and Monoclonal Gammopathy Research Group (2011) The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 8(1):43–51
5. Abbott KC, Agodoa LY (2001) Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 56(3):207–210